0000905718-16-001577.txt : 20160804
0000905718-16-001577.hdr.sgml : 20160804
20160804160043
ACCESSION NUMBER: 0000905718-16-001577
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20160804
DATE AS OF CHANGE: 20160804
EFFECTIVENESS DATE: 20160804
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dance Biopharm Holdings, Inc.
CENTRAL INDEX KEY: 0001650840
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-268368
FILM NUMBER: 161807268
BUSINESS ADDRESS:
STREET 1: 150 NORTH HILL DRIVE, SUITE 24
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 415-369-9415
MAIL ADDRESS:
STREET 1: 150 NORTH HILL DRIVE, SUITE 24
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: Dance BioPharm Holdings, Inc.
DATE OF NAME CHANGE: 20150812
D
1
primary_doc.xml
X0707
D
LIVE
0001650840
Dance Biopharm Holdings, Inc.
150 NORTH HILL DRIVE, SUITE 24
BRISBANE
CA
CALIFORNIA
94005
415-369-9415
DELAWARE
SAV Holdings Corp.
Dance BioPharm Holdings, Inc.
Corporation
true
2013
John
S.
Patton, Ph.D
150 North Hill Drive, Suite 24
Brisbane
CA
CALIFORNIA
94005
Executive Officer
Director
Greg
S.
Zante
150 North Hill Drive, Suite 24
Brisbane
CA
CALIFORNIA
94005
Executive Officer
Lisa
E.
Porter, M.D.
150 North Hill Drive, Suite 24
Brisbane
CA
CALIFORNIA
94005
Executive Officer
Vivian
Yan
150 North Hill Drive, Suite 24
Brisbane
CA
CALIFORNIA
94005
Director
Donald
D.
Huffman
150 North Hill Drive, Suite 24
Brisbane
CA
CALIFORNIA
94005
Director
Adam
Stern
c/o Aegis Capital Corp.
810 Seventh Ave., 18th Floor
New York
NY
NEW YORK
10019
Director
Biotechnology
Decline to Disclose
- 06b
false
2016-06-20
false
true
true
true
Units consisting of common stock and warrants
false
0
Aegis Capital Corp
15007
None
None
810 SEVENTH AVENUE, 18TH FLOOR
NEW YORK
NY
NEW YORK
10019
All States
false
23000000
625000
22375000
Includes over-allotment option.
false
2
2300000
true
0
Placement Agent is entitled to receive 10% cash and expense fees. Assumes maximum offering sold and commissions paid pursuant to over-allotment. Does not include value of warrants issuable to Placement Agent.
0
true
Some of the proceeds may be used for general working capital purposes which may include payment of salaries and other fees to those listed in Item 3, as more fully set forth in the offering materials.
false
Dance Biopharm Holdings, Inc.
/s/ John S. Patton Ph.D
John S. Patton Ph.D
Chief Executive Officer
2016-08-04